Cargando…

Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including solubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, Line Jee Hartmann, Schultz, Martin, Gaardsting, Anne, Ladelund, Steen, Garred, Peter, Iversen, Kasper, Eugen‐Olsen, Jesper, Helms, Morten, David, Kim Peter, Kjær, Andreas, Lebech, Anne‐Mette, Kronborg, Gitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518177/
https://www.ncbi.nlm.nih.gov/pubmed/28393357
http://dx.doi.org/10.1002/ijc.30732
_version_ 1783251442071502848
author Rasmussen, Line Jee Hartmann
Schultz, Martin
Gaardsting, Anne
Ladelund, Steen
Garred, Peter
Iversen, Kasper
Eugen‐Olsen, Jesper
Helms, Morten
David, Kim Peter
Kjær, Andreas
Lebech, Anne‐Mette
Kronborg, Gitte
author_facet Rasmussen, Line Jee Hartmann
Schultz, Martin
Gaardsting, Anne
Ladelund, Steen
Garred, Peter
Iversen, Kasper
Eugen‐Olsen, Jesper
Helms, Morten
David, Kim Peter
Kjær, Andreas
Lebech, Anne‐Mette
Kronborg, Gitte
author_sort Rasmussen, Line Jee Hartmann
collection PubMed
description In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin‐3, mannose‐binding lectin, ficolin‐1, ficolin‐2 and ficolin‐3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C‐reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow‐up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self‐reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin‐1‐3, MBL and pentraxin‐3 were not associated with cancer.
format Online
Article
Text
id pubmed-5518177
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55181772017-08-03 Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer Rasmussen, Line Jee Hartmann Schultz, Martin Gaardsting, Anne Ladelund, Steen Garred, Peter Iversen, Kasper Eugen‐Olsen, Jesper Helms, Morten David, Kim Peter Kjær, Andreas Lebech, Anne‐Mette Kronborg, Gitte Int J Cancer Tumor Markers and Signatures In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin‐3, mannose‐binding lectin, ficolin‐1, ficolin‐2 and ficolin‐3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C‐reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow‐up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self‐reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin‐1‐3, MBL and pentraxin‐3 were not associated with cancer. John Wiley and Sons Inc. 2017-04-24 2017-07-01 /pmc/articles/PMC5518177/ /pubmed/28393357 http://dx.doi.org/10.1002/ijc.30732 Text en © 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Tumor Markers and Signatures
Rasmussen, Line Jee Hartmann
Schultz, Martin
Gaardsting, Anne
Ladelund, Steen
Garred, Peter
Iversen, Kasper
Eugen‐Olsen, Jesper
Helms, Morten
David, Kim Peter
Kjær, Andreas
Lebech, Anne‐Mette
Kronborg, Gitte
Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
title Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
title_full Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
title_fullStr Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
title_full_unstemmed Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
title_short Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
title_sort inflammatory biomarkers and cancer: crp and supar as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer
topic Tumor Markers and Signatures
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518177/
https://www.ncbi.nlm.nih.gov/pubmed/28393357
http://dx.doi.org/10.1002/ijc.30732
work_keys_str_mv AT rasmussenlinejeehartmann inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT schultzmartin inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT gaardstinganne inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT ladelundsteen inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT garredpeter inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT iversenkasper inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT eugenolsenjesper inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT helmsmorten inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT davidkimpeter inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT kjærandreas inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT lebechannemette inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer
AT kronborggitte inflammatorybiomarkersandcancercrpandsuparasmarkersofincidentcancerinpatientswithseriousnonspecificsymptomsandsignsofcancer